Sierra Oncology Inc. (SRRA)

0.42
0.04 9.68
NASDAQ : Health Technology
Prev Close 0.47
Open 0.47
Day Low/High 0.42 / 0.47
52 Wk Low/High 0.40 / 2.01
Volume 129.73K
Avg Volume 412.00K
Exchange NASDAQ
Shares Outstanding 74.69M
Market Cap 33.87M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options To Support Development Of Its DDR Assets

Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options To Support Development Of Its DDR Assets

- Corporate prioritization of portfolio to focus resources on advancement of momelotinib -- Exploring non-dilutive options to support future continued development of SRA737 and SRA141 - VANCOUVER, June 27, 2019 /PRNewswire/ - Sierra Oncology, Inc.

Sierra Announces Momelotinib Granted FDA Fast Track Designation

Sierra Announces Momelotinib Granted FDA Fast Track Designation

-  Fast Track designation highlights the potential for momelotinib to address the significant unmet needs of patients with Intermediate/High-Risk myelofibrosis who have previously received a JAK inhibitor -- Fast Track Designation assures frequent...

Sierra Announces FDA Regulatory Clarity For Momelotinib & Design Of The MOMENTUM Phase 3 Clinical Trial

Sierra Announces FDA Regulatory Clarity For Momelotinib & Design Of The MOMENTUM Phase 3 Clinical Trial

 - MOMENTUM Phase 3 clinical trial planned for launch in Q4 2019; topline efficacy data anticipated in Q4 2021 -- World renowned myelofibrosis expert Dr.

Sierra Holds Analyst & Investor Event For SRA737

Sierra Holds Analyst & Investor Event For SRA737

- Sierra management and distinguished oncologists Professor Johann de Bono and Dr.

Sierra Announces Promising Preliminary Efficacy In SRA737 Clinical Program & Outlines Potential Path To Registration

Sierra Announces Promising Preliminary Efficacy In SRA737 Clinical Program & Outlines Potential Path To Registration

- Sierra reports 30% response rate for SRA737+LDG in anogenital cancer -- Anti-cancer activity demonstrated across multiple indications and genetic contexts in preliminary Phase 1/2 data presentations at ASCO -- Sierra to discuss clinical findings and...

Sierra Oncology To Present Momelotinib And SRA737 Overview At The Jefferies Global Healthcare Conference In New York

Sierra Oncology To Present Momelotinib And SRA737 Overview At The Jefferies Global Healthcare Conference In New York

- Presentation scheduled for 8:00 am ET on June 5, 2019 - VANCOUVER, May 28, 2019 /PRNewswire/ - Sierra Oncology, Inc.

Sierra To Present SRA737 Preliminary Clinical Data And Potential Next Steps At ASCO

Sierra To Present SRA737 Preliminary Clinical Data And Potential Next Steps At ASCO

- SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster presentations on June 1 st -- Sierra to hold Analyst & Investor Event at 6:00 am CT on June 3 rd featuring distinguished oncologists Professor Johann de Bono...

Sierra Oncology Reports First Quarter 2019 Results

Sierra Oncology Reports First Quarter 2019 Results

Momelotinib regulatory pathway clarity anticipated in Q2 2019 -- SRA737 Phase 1/2 preliminary clinical data anticipated at the 2019 ASCO Annual Meeting - VANCOUVER, May 8, 2019 /PRNewswire/ - Sierra Oncology, Inc.

Sierra Oncology To Attend Two Investor Conferences In May

Sierra Oncology To Attend Two Investor Conferences In May

VANCOUVER, May 6, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced...

Sierra Reports Late-Breaking SRA141 Preclinical Data In Poster At AACR 2019

Sierra Reports Late-Breaking SRA141 Preclinical Data In Poster At AACR 2019

- Compelling preclinical data for its Cdc7 inhibitor, SRA141, indicate a potentially novel and distinct mechanism of action - VANCOUVER, April 3, 2019 /PRNewswire/ - Sierra Oncology, Inc.

Sierra Reports Late-Breaking Preclinical Data For SRA737 Presented At AACR 2019

Sierra Reports Late-Breaking Preclinical Data For SRA737 Presented At AACR 2019

- Late-breaking oral presentation reports profound, durable synergistic activity for immunotherapy combined with SRA737+LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung cancer models - VANCOUVER, April 1, 2019 /PRNewswire/...

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.